NASDAQ:VXRT Vaxart (VXRT) Stock Price, News & Analysis $0.35 0.00 (-1.37%) As of 01:06 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Vaxart Stock (NASDAQ:VXRT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vaxart alerts:Sign Up Key Stats Today's Range$0.34▼$0.3750-Day Range$0.30▼$0.7052-Week Range$0.26▼$1.07Volume242,677 shsAverage Volume2.99 million shsMarket Capitalization$80.60 millionP/E RatioN/ADividend YieldN/APrice Target$2.00Consensus RatingBuy Company Overview Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California. Read More Vaxart Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreVXRT MarketRank™: Vaxart scored higher than 55% of companies evaluated by MarketBeat, and ranked 504th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingVaxart has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageVaxart has received no research coverage in the past 90 days.Read more about Vaxart's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vaxart are expected to grow in the coming year, from ($0.39) to ($0.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaxart is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaxart is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaxart has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.62% of the float of Vaxart has been sold short.Short Interest Ratio / Days to CoverVaxart has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vaxart has recently decreased by 8.25%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVaxart does not currently pay a dividend.Dividend GrowthVaxart does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.62% of the float of Vaxart has been sold short.Short Interest Ratio / Days to CoverVaxart has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vaxart has recently decreased by 8.25%, indicating that investor sentiment is improving significantly. News and Social Media1.8 / 5News Sentiment0.28 News SentimentVaxart has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Vaxart this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for VXRT on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Vaxart to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vaxart insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.80% of the stock of Vaxart is held by insiders.Percentage Held by InstitutionsOnly 18.05% of the stock of Vaxart is held by institutions.Read more about Vaxart's insider trading history. Receive VXRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxart and its competitors with MarketBeat's FREE daily newsletter. Email Address VXRT Stock News HeadlinesVaxart Discusses Reverse Stock Split ProposalAugust 21 at 5:30 PM | tipranks.comConcerned Vaxart Stockholders Unite to Oppose Vaxart’s Latest Reverse Stock Split and Defend Stockholder RightsAugust 21 at 11:02 AM | markets.businessinsider.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.August 22 at 2:00 AM | American Alternative (Ad)Concerned Vaxart Stockholders Unite to Oppose Vaxart's Latest Reverse Stock Split and Defend Stockholder RightsAugust 21 at 9:30 AM | globenewswire.comVaxart, Inc. (VXRT) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | seekingalpha.comUS orders Vaxart to stop COVID-19 trial amid mRNA wind downAugust 13, 2025 | reuters.comVaxart, Inc. Stock (VXRT) Opinions on Reverse Stock Split ProposalJuly 31, 2025 | quiverquant.comQVaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on NasdaqJuly 24, 2025 | globenewswire.comSee More Headlines VXRT Stock Analysis - Frequently Asked Questions How have VXRT shares performed this year? Vaxart's stock was trading at $0.6621 at the beginning of the year. Since then, VXRT shares have decreased by 47.1% and is now trading at $0.3501. How were Vaxart's earnings last quarter? Vaxart, Inc. (NASDAQ:VXRT) released its earnings results on Tuesday, May, 13th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). The biotechnology company had revenue of $20.88 million for the quarter, compared to analysts' expectations of $2.85 million. Vaxart had a negative trailing twelve-month return on equity of 91.89% and a negative net margin of 122.63%. Read the conference call transcript. When did Vaxart's stock split? Vaxart shares reverse split on the morning of Wednesday, February 14th 2018.The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split. Who are Vaxart's major shareholders? Top institutional investors of Vaxart include Geode Capital Management LLC (1.02%), Marshall Wace LLP (0.77%), Raymond James Financial Inc. (0.10%) and Invesco Ltd. (0.05%). View institutional ownership trends. How do I buy shares of Vaxart? Shares of VXRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vaxart own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vaxart investors own include Plug Power (PLUG), Workhorse Group (WKHS), FuelCell Energy (FCEL), Fortress Biotech (FBIO), Assertio (ASRT), Ovid Therapeutics (OVID) and KALA BIO (KALA). Company Calendar Last Earnings5/13/2025Today8/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VXRT Previous SymbolNASDAQ:NABI CIK72444 Webwww.vaxart.com Phone(650) 550-3500Fax650-871-8580Employees120Year Founded2004Price Target and Rating Average Price Target for Vaxart$2.00 High Price Target$2.00 Low Price Target$2.00 Potential Upside/Downside+460.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($0.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$66.95 million Net Margins-122.63% Pretax Margin-121.98% Return on Equity-91.89% Return on Assets-38.40% Debt Debt-to-Equity RatioN/A Current Ratio0.64 Quick Ratio0.64 Sales & Book Value Annual Sales$47.40 million Price / Sales1.72 Cash FlowN/A Price / Cash FlowN/A Book Value$0.26 per share Price / Book1.37Miscellaneous Outstanding Shares228,922,000Free Float222,374,000Market Cap$81.73 million OptionableOptionable Beta1.12 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:VXRT) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxart, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxart With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.